Allergan upgraded to Outperform from Market Perform at Wells Fargo Wells Fargo upgraded shares of Allergan to Outperform on expectations new parents for Restasis are likely to be issued in the near-term, delaying generic competition well beyond its previous 2016 assumption. Wells raised its price target range for shares to $121-$122 from $99-$100. Allergan closed yesterday down 34c to $107.39.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.